629 reports of this reaction
1.5% of all MIDAZOLAM reports
#11 most reported adverse reaction
STATUS EPILEPTICUS is the #11 most commonly reported adverse reaction for MIDAZOLAM, manufactured by UCB, Inc.. There are 629 FDA adverse event reports linking MIDAZOLAM to STATUS EPILEPTICUS. This represents approximately 1.5% of all 42,629 adverse event reports for this drug.
Patients taking MIDAZOLAM who experience status epilepticus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
STATUS EPILEPTICUS is a less commonly reported adverse event for MIDAZOLAM, but still significant enough to appear in the safety profile.
In addition to status epilepticus, the following adverse reactions have been reported for MIDAZOLAM:
The following drugs have also been linked to status epilepticus in FDA adverse event reports:
STATUS EPILEPTICUS has been reported as an adverse event in 629 FDA reports for MIDAZOLAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
STATUS EPILEPTICUS accounts for approximately 1.5% of all adverse event reports for MIDAZOLAM, making it a notable side effect.
If you experience status epilepticus while taking MIDAZOLAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.